natgillin/translations-raw huggingface dataset:
Another object of the present invention lies in an alkaline earth metal carbonate-containing product obtained by the process of the invention. 
PROCES PLUTANJA PJENE ZA RAZDVAJANJE SILIKATA | KARBONATA ALKALIJSKIH ZEMNIH METALA POMOCU KOLEKTORA S BAREM JEDNIM HIDROFOBNO MODIFICIRANIM POLIALKILENIMINOM
A process of claim 13, further comprising preparing a compound of Formula IIe by a process comprising reacting a compound of Formula IIc with a compound of Formula IIf: in the presence of a coupling catalyst and a base. 
-borabiciklo[3.3.1]nonanom, nakon čega slijedi reakcija sa spojem s formulom IIc: [image] u prisutnosti paladijevog (II) diacetata da se dobije spoj s formulom IId;
amino acids having a sequence at least 80% identical to a light chain variable domain sequence of L5; 
aminokiseline koje imaju slijed najmanje 80% identičan slijedu SEQ ID NO:363;
1994, 35, 3225-3226 followed by deprotection under standard conditions known to the persons skilled in the art and detailed in the textbook Protective Groups in Organic Synzthesis, Greene and Wuts, Wiley Interscience, (1991), ISBN 0471623016. 
Tetrahedron Lett, 1994., 35, 3225-3226, a potom deprotekcijom pod standardnim uvjetima poznatima struci i opisanima u udžbeniku Protective Groups in Organic Synthesis, Greene i Wuts, Wiley Interscience (1991), ISBN 0471823018.
R2a is hydrogen, C1-6alkyl, C3-8cycloalkyl, C5-8cycloalkenyl, phenyl or 3-8 membered heterocyclic group containing at least one of O, S and N, said C1-6alkyl, C3-8cycloalkyl, C5-8cycloalkenyl, phenyl and 3-8 membered heterocyclic group can be optionally substituted with 1, 2, 3, 4, 5 or 6 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, carboxyl, amino, C1-6alkyl and haloC1-6alkyl; 
R* je vodik, Cigalkil, C3 gcikloalkil, Cs.gcikloalkenil, fenil ili 3-8 člana heterociklična skupina koja sadrži barem jedan od O, S iN, spomenuti C, galkil, Ca gcikloalkil, Cs.gcikloalkenil, fenil i 3-8 člana heterociklična skupina mogu izborno biti supstituirani s 1, 2, 3, 4, 5 ili 6 supstituenata nezavisno odabranih iz skupine koja se sastoji od halogena, cijano, hidroksila, karboksila, amino, Ci salkila i haloC, salkila;
A glucocorticoid contained in a delayed-release dosage form for use according to any one of the previous claims, wherein said treatment consists of administering to said patient an effective amount of a glucocorticoid contained in a delayed-release dosage form, wherein said treatment is administered once daily in the evening for at least two weeks. 
Glukokortikoid sadržan u obliku doziranja s odgođenim otpuštanjem za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu navedeno liječenje obuhvaća davanje navedenom bolesniku učinkovite količine glukokortikoida sadržane u obliku doziranja s odgođenim otpuštanjem, pri čemu je navedeno liječenje primijenjeno jednom dnevno kroz najmanje dva tjedna.
An opioid agonist compound comprising a residue of an opioid agonist covalently attached to a water-soluble, non-peptidic oligomer, the compound having the formula: wherein: 
Spoj opioidnog agonista koji sadrži ostatak opioidnog agonista kovalentno vezan na u vodi topiv, ne-peptidni oligomer, te spoj ima formulu: [image] naznačen time da:
The pharmaceutical combinations according to the invention may contain (a) and (b) generally in a ratio by weight (b):(a) ranging from 1:100 to 100:1, preferably from 1:50 to 50:1. 
Farmaceutske kombinacije sukladno predmetnom izumu mogu sadržavati (a) 1 (b) općenito u težinskim omjerima (b):(a) u rasponu od 1:5 do 500:1, poželjno u rasponu od 1:10 do
The components (B) are known. 
(B) spoj ciprodinil.
Set C is the three dimensional library that consists of all permutations of all of the variants of R1 represented in Set A, all of the R2 variants listed above for Set B, and a set of R3 variants listed below. 
Skupina C je trodimenzionalna kolekcija koja se sastoji od svih permutacija od svih varijacija R' koje su prikazane u Skupini A, od svih R* varijacija koje su gore navedene za Skupinu B i skupinu R* niše navedenih varijacija. U skupini C
A composition according to claim 9 or claim 14, wherein the recombinant alpha-mannosidase remains stable in liquid solution for at least 4 days when stored at +5 °C or for at least 24 months when stored at -20 °C. 
Pripravak u skladu s patentnim zahtjevom 16, naznačen time što rekombinantna a-manozidaza ostaje stabilna u tekućoj otopini najmanje 4 dana prilikom skladištenja na +5 "C ili najmanje 24 mjeseca prilikom skladištenja na - 20 *C.
The nitrile (AF) is treated with an excess of borane-THF solution in a solvent like THF at low temperature, followed by oxidation with hydrogen peroxide in the presence of sodium hydroxide to give a I:I mixture of alcohols shown as (AG') and (AG"). 
Nitril (AF) se tretira sa suviškom boran-THF otopine u otapalu poput THF pri niskoj temperaturi, nakon čega slijedi oksidacija s vodikovim peroksidom u prisutnosti natrij hidroksida da bi se dobila 1:1 smjesa alkohola prikazana kao (AG') i (AG"').
Removal of solvent under reduced pressure yields diethyl ester of 3-oxocyclopentane-1,1-dicarboxylic acid. 
Uklanjanjem otapala pod sniženim tlakom dobiva se dietilni ester 3- oksociklopentan-1,1-dikarboksilne kiseline.
The panel (1) according to claim 14, wherein the extension of the second sheet (7) is in contact with the second flat surface (9) of the second sheet (7). 
Ploča (1) prema zahtjevu 14, naznačena time što je proširenje druge ploče (7) u doticaju s drugom ravnom površinom (9) druge ploče (7). t>&
The compositions of the invention may be administered with or formulated for administration with the adjuvant, either sequentially or simultaneously, in the same or separate compositions. Thus the compositions of the invention may, but need not, comprise an adjuvant. 
Uporaba prema zahtjevu 10 ili zahtjevu 11, naznačena time, da se sastav primjenjuje, ili se formulira za davanje sa sljedećima: pomoćno sredstvo, primjerice retinoinska kiselina, CD40-agonist ili TLR-agonist, IL-1 ili TNF-alfa.
An antibody or antigen-binding fragment according to claim 1, comprising the HCVR/LCVR pair of SEQ ID NO: 3/11. 
Antitijelo ili njegov fragment koji se veže na antigen u skladu s patentnim zahtjevom 1, naznačeno time, da sadrži HCVR/LCVR parove SEQ ID NO: 19/27 ili 147/155.
a fourth software module executable by the processor and the memory, the fourth software module configured to repair (106) the invalid field of the portable executable file based upon, at least in part, the repair model. 
Sustav u skladu s patentnim zahtjevom 11, naznačen time što dodatno sadrži deveti programski modul, kojeg može izvršiti procesor s memorijom, gdje je deveti programski modul konfiguriran za usklađivanje ispravljene prijenosne izvršne datoteke.
Further, the fact that d-methadone would be beneficial in the treatment of psychiatric symptoms and conditions suggests that similar drugs, such as d-methadol, d-alpha-acetylmethadol, I-alpha-acetylmethadol, d-alpha-normethadol, I-alpha-normethadol, and their pharmaceutically acceptable salts, would also be beneficial in such treatment. A substance selected from the group consisting of d-methadone, d-methadol, d-alpha-acetylmethadol, d-alpha-normethadol, I-alpha-normethadol, pharmaceutically acceptable salts thereof, and mixtures thereof for use in treating psychological and psychiatric symptoms in a subject, wherein the psychological symptoms include depression, anxiety, fatigue, and/or mood instability including pseudo-bulbar affect; 
HR P20181481 T1 PATENTNI ZAHTJEVI Tvar koja je izabrana iz skupine koja se sastoji od d-metadona, d-metadola, d-alfa-acetilmetadola, d-alfa- normetadola, I-alfa-normetadola, njihovih farmaceutski prihvatljivih soli, i njihovih smjesa za uporabu u liječenju psiholoških i psihijatrijskih simptoma kod subjekta, pri čemu psihološki simptomi uključuju depresiju, anksioznost, umor, i/ili nestabilnost raspoloženja, uključujući pseudo-bulbarni utjecaj; pri čemu je tvar izolirana iz njegovog enantiomera ili sintetizirana de novo; i pri čemu se tvar može vezati na: receptor NMDA (N-metil-D-aspartat) subjekta i/ili receptor NE (norepinefrin) subjekta.
/ Formulation of IL-2 microaggregates for pharmaceutical use 
2/ Formuliranje mikroagregata IL-2 za farmaceutsku uporabu
A method according to claim 1 or 2, characterized in that the first and second segments of the rim portion (5) are successive segments and bent relative to each other to a substantially right angle, and that the first and second segments of the folding portion (7) are successive segments and bent relative to each other to an angle of more than 90°and less than 180°. 
Postupak prema zahtjevu 1 ili 2, naznačen time da su prvi i drugi segmenti rubnog dijela (5) uzastopni segmenti i međusobno su savijeni uglavnom pod pravim kutem, te da su prvi i drugi segmenti preklopnog dijela (7) uzastopni segmenti i međusobno su savijeni pod kutem većim od 90 * 1 manjim od 180 ".
The composition of claim 1, wherein the 4-1BB costimulatory signaling region comprises the amino acid sequence of SEQ ID NO:23. 
(i) - kostimulatorno signalno područje 4-1 BB sadrži aminokiselinsku sekvencu naznačenu u SEQ ID NO: 23;
The antibody or pharmaceutical composition according to claim 16 for said use, wherein the pathological disorder is selected from the group consisting of arthritis, rheumatoid arthritis, psoriatic arthritis, systemic onset juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE), asthma, Crohn's disease, ulcerative colitis, Castleman's disease, ankylosing spondylitis and cancer. 
Antitijelo ili farmaceutski sastav prema zahtjevu 16 za spomenutu upotrebu, pri čemu je patološki poremećaj izabran iz grupe koju čine artritis, reumatoidni artritis, psorijatički artritis, sistemski nastanak juvenilnog idiopatskog artritisa (JIA), sistemski eritematozni lupus (SLE), astma, Kronova bolest, ulcerativni kolitis, Kastlemanova bolest, ankilozni spondilitis 1 rak.
The method according to claim 6, wherein the raw materials are selected from the group consisting of aromas and plant extracts, and wherein growth-promoting ingredients are selected from the group consisting of antibiotics, probiotics, prebiotics, essential oils, enzymes, fatty acids and organic acids. 
Dodatak prehrani prema zahtjevu 3, gdje se sirovi materijali izabiru iz grupe koju čine arome i biljni ekstrakti, i gdje se tvari za poticanje rasta izabiru iz grupe koju čine antibiotici, probiotici, prebiotici, esencijalna ulja, enzimi, masne kiseline i organske kiseline.
Other suitable emollients which are solids or semi-solids at ambient temperatures may be used. 
Mogu se upotrijebiti drugi prikladni emolijenti koji su krutine ili polu-krutine na sobnoj temperaturi.
The pharmaceutical composition of claim 12, wherein the compound is 6-bromo-8-(methyl-D3)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid, or a salt thereof. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema patentnom zahtjevu 2, naznačeno time što je spoj 6-bromo-8-(metil-D3)-2-(trifluorometil)-2H-kromen-3-karboksilna kiselina.
Note that the defined criterion can for example be a predefined time period after initiating the steam production operation and/or a threshold temperature value. 
Treba primijetiti da definirani kriterij može primjerice biti prethodno određeni vremenski period nakon pokretanja operacije proizvodnje vodene pare 1/ili postizanja granične vrijednosti temperature.
A combination according to claim 8, wherein the active compound (c) is selected from the group consisting of (a) PDE IV inhibitors and (b) B2 agonists. 
Kombinacija u skladu s patentnim zahtjevom 8, naznačena time, da je djelatna tvar (c) odabrana iz skupine koja se sastoji od (a) inhibitora PDE IV i (b) B2 agonista.
The dihydrotetrabenazine isomers (V) are reacted with a dehydrating agent such as phosphorus pentachloride in a non-protic solvent such as a chlorinated hydrocarbon (for example chloroform or dichloromethane, preferably dichloromethane) to form the unsaturated compound (II) as a pair ofenantiomers, only the R -enantiomer of which is shown in the Scheme. 
Dihidrotetrabenazin izomeri (V) reagiraju sa sredstvom za dehidriranje poput fosfor pentaklorida u ne-protičnom otapalu poput kloriranog ugljikovodika (na primjer kloroforma ili diklorometana, povoljan je diklorometan) da bi se formirao nezasićen spoj (II) kao par enantiomera, od kojih je jedino R-enantiomer prikazan u Shemi.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in a method according to embodiment 1, wherein the LSD is chosen from Tay-Sachs disease, the AB variant of Tay-Sachs disease, Sandhoff disease, Niemann-Pick type A disease, Niemann-Pick type B disease, Fabry disease, neuronal ceroid lipofuscinoses, Krabbe disease, Farber disease, Gaucher disease, metachromatic leukodystrophy, multiple sulphatase deficiency, mucolipidosis II, mucolipidosis III, MPS III, MPS VII, GM1 gangliosidosis, and aspartylglucosaminuria. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 1, pri čemu je LSD odabran od Tay-Sachsove bolesti, AB varijante Tay-Sachsove bolesti, Sandhoffove bolesti, Niemann-Pick bolesti tipa A, Niemann-Pick bolesti tipa B, Fabryjeve bolesti, neuronske ceroidne lipofuscinoze, Krabbove bolest, Farberove bolesti, Gaucherove bolesti, metakromatske leukodistrofije, multiple deficijencije sulfataze, mukolipidoze II, mukolipidoze III, MPS III, MPS VII, GMI gangliozidoze i aspartilglukozaminurije.
has a genome which is isogenic to wild-type E . coli strain W3110 except for the mutated Tsp gene and the mutated sprgene. 
ima genom koji je izogen divljem-tipu E. coli soja W3110 osim za mutirani Tsp gen i mutirani spr gen.
The process according to any one of claims 1-5, wherein the activating agent in step a2) is selected from a halogenating agent, C1-4alkyl acid halide, aryl acid halide, benzyl acid halide, C1-4alkyl haloformate, aryl haloformate, and benzyl haloformate. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što se aktivacijsko sredstvo u koraku a2) bira između halogenacijskog sredstva, halogenida C1-4alkilne kiseline, izborno supstituiranog halogenida arilne kiseline, halogenida benzilne kiseline, C1-4alkil-halogenformijata, izborno supstituiranog aril-halogenformijata i benzil-halogenformijata.
a motor for driving a transfer of the extraction module between the closed state and the opened state; and 
- < motor (12) za upravljanje s premještanjem modula za ekstrakciju između zatvorenog i otvorenog položaja, i
Package according to claim 6, characterized in that it also comprises a small quantity of cooking liquid (11), limpid and clear, and/or a minimum presence of albumin proteins (14) exudate from said one or more portions of fish in the solid form (10) during cooking, mainly adhered to the surface of said one or more portions of fish in the solid form (10). 
Pakiranje sukladno zahtjevu 6, naznačeno time što također obuhvaća malu količinu tekućine za kuhanje (11), bistre i čisto, i/ili minimalnu količinu proteina albumina (14) eksudata iz jedne ili više porcija ribe u čvrstom obliku (10) tijekom kuhanja, ponajviše uz površinu jedne ili više porcija ribe u čvrstom obliku (10).
The method according to claim 9, wherein said additional integral action is set proportional to a spring-constant or spring stiffness of said drill string modelled as a torsional spring. 
Postupak sukladno zahtjevu 9, pri čemu je navedeno integralno djelovanje (Al; 49) prilagođeno proporcionalno konstanti opruge ili čvrstoći opruge navedene bušilice (12) modelirane kao torzijska opruga.
The set as claimed in claim 9, wherein the first locking strip is arranged at the first edge, and an outer and lower part of the displaceable tongue is provided with a recess. 
Komplet prema patentnom zahtjevu 5, naznačen time što je prva traka za zaključavanje postavljena na prvom rubu, a vanjski i donji dio pomičnog jezičca (30) ima udubljenje (31).
determining a number of actual counts of the respective first allele based on the sequencing of the plurality of nucleic acid molecules from the biological sample; and 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što statistička raspodjela ovisi o frakcionalnoj koncentraciji molekula nukleinske kiseline iz biološkog uzorka dobivenih iz fetusa.
At the third technological stage, in case of need the obtained salts are recrystallised from a suitable solvent. 
U trećem tehnološkom stupnju, u slučaju potrebe, dobivene soli se prekristaliziraju iz prikladnog otapala.
The process according to any one of claims 4 or 6, wherein the compound of formula (V) is obtained by reacting compound of formula (IV) with C1-4alkanol and an acid catalyst; and wherein the compound of formula (IV) is obtained by reacting compound of formula (III) with benzyl alcohol; in the presence of a coupling agent; or in the presence of an C1-4alkylchloroformate of the formula ClCOOR", wherein R'' is C1-4alkyl, such as methyl, ethyl, 1-propyl, 1-butyl, 2-butyl, and an organic base. 
Postupak prema bilo kojem zahtjevu 4 ili 6, naznačen time da je spoj formule (V) dobiven reakcijom spoja formule (IV) sa Crvalkanolom i kiselim katalizatorom; te pri čemu je spoj formule (TV) dobiven reakcijom spoja formule (II) sa benzil alkoholom; u prisutnosti reakcijskog sredstva ili u prisutnosti C,galkilkloroformata formule CICOOR", pri čemu R" je Craalkil, kao metil, etil, 1-propil, 1-butil, 2-butil, i organske baze.
reacting two donor compounds having a formula I: where R groups are -R"OR"' group, where R" is a methylene and R'" is a linear or branched C2 to C30 alkyl and R' is methyl with a conjugated acceptor compound comprising an acceptor moiety, wherein the conjugated acceptor compound comprising an acceptor moiety is to form a polymerizable unit; and linking covalently a plurality of the polymerizable units at ends of said polymerizable units to form the conjugated polymer, wherein the conjugated polymer absorbs radiation within a first band of the visible spectrum and a second band of the visible spectrum and is green in the neutral state and upon oxidation the polymer is transmissive with absorbance of radiation within the first and second bands being less than in the neutral state, and wherein the polymer is soluble in at least one solvent. 
Postupak formiranja konjugiranog polimera, postupak obuhvaća korake: reakcija dva donor spoja formule I: gdje su R skupine -R"OR"' skupina, gdje je R" metilen i R'" je linearni ili razgranati C2 do C30 alkil i R' je metil, s konjugiranim prihvatnim spojem koji ima prihvatni dio, gdje je konjugirani prihvatni spoj s prihvatnim dijelom da formiraju jedinicu koja se može polimerizirati; 1 kovalentno povezivanje niza jedinica koje se mogu polimerizirati na krajevima tih jedinica koje se mogu polimerizirati radi formiranja konjugiranog polimera, gdje konjugirani polimer apsorbira zračenje iz prve vrpce vidljivog spektra i druge vrpce vidljivog spektra i zelen je u neutralnom stanju, a nakon oksidacije polimer je propusan s apsorbiranjem zračenja unutar prve 1 druge vrpce koje je manje nego u neutralnom stanju, i gdje je polimer topljiv u barem jednom otapalu.
A process for producing a nutritional supplement according to embodiment 33, said process comprising admixing the bacterial species Roseburia hominis with a nutritionally acceptable excipient, carrier or diluent. 
Postupak za proizvodnju nutritivnog dodatka prema zahtjevu 3, naznačen time što sadrži miješanje bakterijske vrste Roseburia hominis sa nutritivno prihvatljivim ekscipijensom, nosačem ili diluentom.
In other embodiments, the condition is liver disease, such as fatty liver disease or hepatitis. 
Farmaceutski pripravak za uporabu prema zahtjevu 45, naznačen time da je bolest jetre, bolest masne jetre ili hepatitis.
phenyl or a 5-6 membered heteroaryl or a heterocyclic group attached at any available point and being optionally substituted with 1-3 groups, 1-3 of which are halo, C1-3alkyl or haloC1-3alkyl groups, 1-2 of which are OC1-3alkyl or haloOC1-3alkyl groups, and 1 of which is selected from the group consisting of: 
fenil ili heteroaril s 5-6 članova ili heterociklička skupina spojena na bilo koju dostupnu točku, po izboru supstituirani s 1-3 skupine od kojih su 1-3 halogen, C1-3alkil ili halogenC1-3alkil skupina, a 1-2 su skupina OC1-3alkil ili halogenOC1-3alkil, a 1 se izabire iz grupe koja obuhvaća
More specifically (Figure 3), fast cut-off circuit 4 operates as follows. 
Određenije, (Slika 3) komunikacijski krug brzog isključivanja 4 radi kako slijedi.
Therefore, the locking part(s) are preferably arranged close to indentations, that is used to open and close the packaging like a book, in order to reduce the amount of force to close and to make sure that the packaging is closed in one step. 
Stoga je poželjno da su dijelovi koji osiguravaju zatvaranje smješteni u blizini nazubljenja, kakvo se koristi kod otvaranja i zatvaranja pakiranja koje ima oblik knjige, da bi se smanjila veličina sile za zatvaranje i da bi se osiguralo da se pakiranje zatvara u jednom koraku.
Use of the surface-reacted calcium carbonate obtainable by the process according to any of claims 1 to 20, wherein the surface is partially reacted with weak acids selected from boric acid, citric acid, sodium dihydrogen citrate, potassium dihydrogen citrate, disodium hydrogen citrate, dipotassium hydrogen citrate, sodium dihydrogen borate, potassium dihydrogen borate, disodium hydrogen borate, dipotassium hydrogen borate and mixtures thereof, in paper, tissue paper, plastics, paints or as a controlled release or water treatment agent. 
Uporaba površinski reaktivnog kalcijevog karbonata dobivenog pomoću postupka prema bilo kojem od zahtjeva 1 do 20, naznačen time da površina djelomično reagira sa slabim kiselinama odabranim od borne kiseline, limunske kiseline, natrijevog dihidrogen citrata, kalijevog dihidrogen citrata, dinatrijevog hidrogen citrata, dikalijevog hidrogen citrata, natrijevog dihidrogen borata, kalijevog dihidrogen borata, dinatrijevog hidrogen borata, dikalijevog hidrogen borata i njihovih mješavina, kod papira, toaletnog papira, plastike, kod boja ili kao sredstvo sa kontroliranim otpuštanjem ili kao sredstvo za obradu vode.
A dispensing assembly according to any preceding claim, wherein the container comprises a container seal-forming surface and the spray dispenser comprises a sealing member for forming a seal against the container seal- forming surface to inhibit ingress of air into the container. 
Raspršivač prema bilo kojem prethodnom zahtjevu, pri čemu spremnik sadrži površinu spremnika koja oblikuje brtvu i raspršivač sadrži element za brtvljenje (107) za oblikovanje brtve nasuprot površine spremnika koja oblikuje brtvu kako bi se spriječio ulazak zraka u spremnik.
A method for preparing the formulation according to any of items 1-36, comprising the steps of: Optionally sieving or milling crystals of fumaric acid ester; Blending of said crystals of fumaric acid ester, a rate-controlling agent in the form of a polymeric matrix material, and any pharmaceutically acceptable excipients and additives by direct compression to obtain a tablet formulation; 
Postupak za pripravljanje formulacije prema bilo kojem zahtjevu od 1 do 16, naznačen time, da obuhvaća sljedeće korake: a) opcijski prosijavanje ili mljevenje kristala estera fumarne kiseline; b) sastavljanje spomenutih kristala estera fumarne kiseline, sredstva za kontrolu učestalosti u obliku materijala polimernog matriksa i bilo kojeg farmaceutski prihvatljivog pomoćnog sredstva i dodatka pomoću izravnog stlačivanja za dobivanje formulacije tablete;
The at least one physiologically acceptable solvent (component c)) is usually employed in an amount suitable in order to impart the above noted properties. 
Obično se koristi barem jedno fiziološki prihvatljivo otapalo (sastojak c)) u količini koja je pogodna za ostvarivanje gore navedenih svojstava.